Glenmark Pharmaceuticals Ltd

Mid Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Glenmark Pharmaceuticals is recommended as a 'Buy' with a target price of ₹2,230 and a stop-loss at ₹2,010. The stock exhibits a bullish setup, sustaining above key moving averages and showing signs of demand at lower levels. Momentum indicators suggest a positive bias, indicating potential trend continuation.

Glenmark Pharmaceuticals Shows Bullish Momentum - 26 Feb, 2026

Glenmark Pharmaceuticals faces mixed analyst sentiments. Motilal Oswal sets a target of Rs 2,240, while ICICI Securities recommends a SELL with a target of Rs 1,640, citing muted US growth and margin pressures.

Mixed Analyst Ratings for Glenmark Pharmaceuticals - 04 Feb, 2026

Glenmark Pharmaceuticals reported a 15.1% revenue growth and plans to achieve 115 days of net working capital by March '26. The company is also expanding its product pipeline with multiple ANDAs submitted for North America.

Glenmark Reports Growth and Strategic Plans for FY26 - 03 Feb, 2026

Glenmark Pharmaceuticals reported a 16% increase in Q3 net profit and a 15% rise in revenue. The company faced GST inspections but confirmed no financial impact.

Glenmark Reports Strong Q3 Results Amid Inspections - 01 Feb, 2026

Glenmark Pharmaceuticals announced a 15.88% increase in net profit to ₹403 crore for Q3 2025, with revenue rising 17.75% to ₹3,888 crore, reflecting strong financial performance.

Glenmark Pharmaceuticals Reports Strong Q3 Earnings - 31 Jan, 2026

Glenmark Pharmaceuticals reported robust Q3 results with a net profit of ₹4 billion and revenue of ₹39 billion. EBITDA surged to ₹9 billion, reflecting strong growth across key markets.

Glenmark Pharma Reports Strong Q3 Financials - 30 Jan, 2026

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

In the last 1 year, GLENMARK has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

This section gives you an insight into why this company has been the best in its industry for the last 1 year.

Best in 1 Year

Mutual Funds have increased holdings from 16.31% to 17.86% in Dec 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Up

In the last 1 year, GLENMARK stock has moved up by 58.8%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Rise

In the last 3 years, GLENMARK has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

This section gives you an insight into why this company has been the best in its industry for the last 3 years.

Best in 3 Years

Retail Investor have increased holdings from 13.97% to 14.02% in Dec 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Up

Promoters holdings remained unchanged at 46.65% of holdings in Dec 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

Revenue is down for the last 2 quarters, 6.24K Cr → 3.94K Cr (in ₹), with an average decrease of 36.9% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Fall

Netprofit is down for the last 2 quarters, 610.35 Cr → 403.21 Cr (in ₹), with an average decrease of 33.9% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Down

Foreign Institutions have decreased holdings from 20.73% to 19.20% in Dec 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Down

S&P BSE 150 MidCap

Nifty Midcap 150

Nifty 200

Nifty Healthcare

Nifty LargeMidcap 250

S&P BSE 250 LargeMidCap

Nifty Midcap 100

S&P BSE 400 MidSmallCap

BSE Healthcare

S&P BSE Momentum

BSE 500

Nifty Alpha 50

NIFTY PHARMA

Nifty MidSmallcap 400

Nifty 500

HDFC Mid Cap Fund -Direct Plan - Growth Option

Invesco India Mid Cap Fund Direct Plan Growth Option

Invesco India Contra Fund Direct Plan Growth

ICICI Prudential Equity Arbitrage Fund Direct Plan Growth

SBI Arbitrage Opportunities Fund Direct Growth

Glenmark Pharmaceuticals Ltd’s net profit jumped 15.88% since last year same period to ₹403.21Cr in the Q3 2025-2026. On a quarterly growth basis, Glenmark Pharmaceuticals Ltd has generated -33.94% fall in its net profits since last 3-months.

Glenmark Pharmaceuticals Ltd Earnings Results

In the quarter ending June 2025, Glenmark Pharmaceuticals Ltd has declared dividend of ₹2.50 per share on 26 Sep 2025 - translating a dividend yield of 0.24%.

Name	Value	Action
MACD level (12,26)	1.54	Bullish
CCI (20)	-222.22	Bullish
RSI (14)	56	Neutral
Momentum (10)	3.1	Bearish
ADI (14)	30.36	Bullish
Ultimate Oscillator (7,14,28)	69.06	Neutral

Name	Value	Action
SMA (20)	2123.36	Bullish
EMA (20)	2123.86	Bullish
VWMA (20)	2124.38	Bullish
SMA (50)	2120.93	Bullish
EMA (50)	2121.51	Bullish
SMA (200)	2111.78	Bullish
EMA (200)	2114.01	Bullish
KAMA (200)	2120.29	Bullish
DEMA (200)	2122.12	Bullish

Glenmark Pharmaceuticals Ltd (GLENMARK)

Summary

Overall

Oscillators

Moving Averages